CU20140103A7 - Compuestos de cromano sustituidos como modulares del receptor sensible al calcio - Google Patents
Compuestos de cromano sustituidos como modulares del receptor sensible al calcioInfo
- Publication number
- CU20140103A7 CU20140103A7 CU2014000103A CU20140103A CU20140103A7 CU 20140103 A7 CU20140103 A7 CU 20140103A7 CU 2014000103 A CU2014000103 A CU 2014000103A CU 20140103 A CU20140103 A CU 20140103A CU 20140103 A7 CU20140103 A7 CU 20140103A7
- Authority
- CU
- Cuba
- Prior art keywords
- modular
- calcium
- sensitive
- receptor
- casr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
Abstract
La presente invención proporciona moduladores del receptor sensible al calcio (CaSR). En particular, los compuestos descritos en la presente son útiles para tratar, manejar y/o reducir la gravedad de enfermedades, trastornos, síndromes y/o afecciones asociados con la modulación de los receptores sensibles al calcio (CaSR). La invención también proporciona en la presente las composiciones farmacéuticas de los mismos y métodos para tratar, manejar y/o reducir la gravedad de enfermedades, trastornos, síndromes y/o afecciones asociados con la modulación de CaSR. La invención también se refiere a un proceso para la preparación de los compuestos de la invención. ESPACIO PARA FÓRMULA
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN178KO2012 | 2012-02-24 | ||
| IN1030KO2012 | 2012-09-07 | ||
| PCT/IB2013/051445 WO2013124828A1 (en) | 2012-02-24 | 2013-02-22 | Substituted chroman compounds as calcium sensing receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20140103A7 true CU20140103A7 (es) | 2015-01-29 |
| CU24325B1 CU24325B1 (es) | 2018-03-13 |
Family
ID=54261188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CUP2014000103A CU24325B1 (es) | 2012-02-24 | 2013-02-22 | Compuestos de cromano sustituidos como modulares del receptor sensible al calcio para tratar enfermedades o desórdenes asociados con estos moduladores |
Country Status (44)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE046172T2 (hu) * | 2012-02-24 | 2020-02-28 | Lupin Ltd | Szubsztituált krománvegyületek mint kalcium-szenzor receptor modulátorok |
| JP2015528462A (ja) * | 2012-08-27 | 2015-09-28 | ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ | カルシウム感知受容体モジュレーターとしてのアリールアルキルアミン化合物 |
| TW201602062A (zh) | 2013-08-12 | 2016-01-16 | 魯賓有限公司 | 取代聯苯基化合物作為鈣敏感受體調節劑 |
| AU2014313835A1 (en) | 2013-08-28 | 2016-03-03 | Lupin Atlantis Holdings Sa | Substituted naphthalene compounds as calcium sensing receptor modulators |
| WO2015162538A1 (en) | 2014-04-21 | 2015-10-29 | Lupin Limited | Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease |
| WO2017037616A1 (en) | 2015-08-31 | 2017-03-09 | Lupin Limited | Arylalkylamine compounds as calcium sensing receptor modulators |
| EP4061805A1 (en) | 2019-11-19 | 2022-09-28 | Lupin Limited | Process for preparing chroman compounds |
| MX2022007939A (es) | 2019-12-27 | 2022-07-27 | Lupin Ltd | Composiciones farmaceuticas de moduladores de casr y metodos y usos de las mismas. |
| CA3166512A1 (en) * | 2020-01-17 | 2021-07-22 | Lupin Limited | Methods, processes and intermediates for preparing chroman compounds |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3063585D1 (en) * | 1979-05-19 | 1983-07-07 | Beecham Group Plc | Chroman derivatives, processes for their preparation and pharmaceutical compositions containing them |
| US5387587A (en) * | 1986-12-23 | 1995-02-07 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Chroman derivatives |
| US6133277A (en) | 1997-12-05 | 2000-10-17 | Janssen Pharmaceutica N.V. | (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties |
| FR2809396B1 (fr) | 2000-05-24 | 2005-10-14 | Centre Nat Rech Scient | Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation |
| FR2812875B1 (fr) | 2000-08-08 | 2003-12-12 | Centre Nat Rech Scient | Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation |
| WO2004069793A2 (en) | 2003-01-28 | 2004-08-19 | Bristol-Myers Squibb Company | Novel 2-substituted cyclic amines as calcium sensing receptor modulators |
| WO2004106280A1 (ja) | 2003-05-28 | 2004-12-09 | Japan Tobacco Inc. | ＣａＳＲアンタゴニスト |
| CN101175724B (zh) | 2005-05-19 | 2011-12-07 | 安斯泰来制药有限公司 | 吡咯烷衍生物或其盐 |
| TW200815388A (en) | 2006-04-18 | 2008-04-01 | Wyeth Corp | Chromane and chromene derivatives and uses thereof |
| MX2009003673A (es) | 2006-10-04 | 2009-04-22 | Pfizer Prod Inc | Derivados de piridido[4,3-d]pirimidin-4(3h)-ona como antagonistas de los receptores de calcio. |
| JP5470653B2 (ja) * | 2006-10-26 | 2014-04-16 | アムジエン・インコーポレーテツド | カルシウム受容体調節剤 |
| CA2669635A1 (en) | 2006-11-16 | 2008-05-22 | Astellas Pharma Inc. | Piperidine derivative or salt thereof |
| AU2008311974B2 (en) * | 2007-10-15 | 2013-11-21 | Amgen Inc. | Calcium receptor modulating agents |
| KR20100108348A (ko) | 2007-11-23 | 2010-10-06 | 레오 파마 에이/에스 | 질병 치료용의 신규한 사이클릭 탄화수소 화합물 |
| KR101700152B1 (ko) | 2008-10-03 | 2017-01-26 | 이에이 파마 가부시키가이샤 | ＣａＳＲ 효능제 |
| WO2010042642A1 (en) | 2008-10-08 | 2010-04-15 | Amgen Inc. | Calcium receptor modulating agents |
| WO2010136037A1 (en) | 2009-05-27 | 2010-12-02 | Leo Pharma A/S | Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof |
| WO2010150837A1 (ja) | 2009-06-25 | 2010-12-29 | 第一三共株式会社 | インドリン誘導体 |
| US20130261132A1 (en) | 2010-11-26 | 2013-10-03 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
| US20130245084A1 (en) | 2010-11-26 | 2013-09-19 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
| JP2014500882A (ja) | 2010-11-26 | 2014-01-16 | レオ ファーマ アクティーゼルスカブ | カルシウム感知受容体活性化合物 |
| CA2828415A1 (en) | 2011-03-10 | 2012-09-13 | Lupin Limited | Substituted morpholines as modulators for the calcium sensing receptor |
| JP6033835B2 (ja) | 2011-03-18 | 2016-11-30 | ルピン アトランティス ホールディングス エスエー | カルシウム感知受容体モジュレーターとしてのベンゾ［ｂ］［１，４］オキサジン誘導体 |
| HUE046172T2 (hu) * | 2012-02-24 | 2020-02-28 | Lupin Ltd | Szubsztituált krománvegyületek mint kalcium-szenzor receptor modulátorok |
-
2013
- 2013-02-22 HU HUE13712928A patent/HUE046172T2/hu unknown
- 2013-02-22 BR BR112014021133-7A patent/BR112014021133B1/pt active IP Right Grant
- 2013-02-22 NZ NZ628627A patent/NZ628627A/en unknown
- 2013-02-22 KR KR1020147025242A patent/KR102041154B1/ko active IP Right Grant
- 2013-02-22 WO PCT/IB2013/051445 patent/WO2013124828A1/en active Application Filing
- 2013-02-22 DK DK13712928.4T patent/DK2817299T3/da active
- 2013-02-22 SG SG11201405117SA patent/SG11201405117SA/en unknown
- 2013-02-22 MY MYPI2014702272A patent/MY171374A/en unknown
- 2013-02-22 EP EP13712928.4A patent/EP2817299B1/en active Active
- 2013-02-22 CU CUP2014000103A patent/CU24325B1/es unknown
- 2013-02-22 GE GEAP201313579A patent/GEP20186911B/en unknown
- 2013-02-22 JP JP2014558258A patent/JP6114316B2/ja active Active
- 2013-02-22 MX MX2014010139A patent/MX355670B/es active IP Right Grant
- 2013-02-22 RS RSP20191101 patent/RS59172B1/sr unknown
- 2013-02-22 PL PL13712928T patent/PL2817299T3/pl unknown
- 2013-02-22 US US14/380,632 patent/US9163001B2/en active Active
- 2013-02-22 PE PE2014001297A patent/PE20142281A1/es active IP Right Grant
- 2013-02-22 PT PT13712928T patent/PT2817299T/pt unknown
- 2013-02-22 ES ES13712928T patent/ES2743492T3/es active Active
- 2013-02-22 UA UAA201410409A patent/UA112679C2/uk unknown
- 2013-02-22 IN IN1672MUN2014 patent/IN2014MN01672A/en unknown
- 2013-02-22 SI SI201331561T patent/SI2817299T1/sl unknown
- 2013-02-22 EA EA201491582A patent/EA026940B9/ru unknown
- 2013-02-22 CN CN201380021510.0A patent/CN104350047B/zh active Active
- 2013-02-22 CA CA2864332A patent/CA2864332C/en active Active
- 2013-02-22 LT LTEP13712928.4T patent/LT2817299T/lt unknown
- 2013-02-22 AU AU2013223715A patent/AU2013223715B2/en active Active
- 2013-02-22 AP AP2014007919A patent/AP2014007919A0/xx unknown
- 2013-02-23 TW TW102106358A patent/TWI617549B/zh not_active IP Right Cessation
- 2013-02-25 AR ARP130100556A patent/AR090135A1/es active IP Right Grant
-
2014
- 2014-08-14 TN TNP2014000352A patent/TN2014000352A1/fr unknown
- 2014-08-15 ZA ZA2014/05990A patent/ZA201405990B/en unknown
- 2014-08-20 CL CL2014002218A patent/CL2014002218A1/es unknown
- 2014-08-20 PH PH12014501891A patent/PH12014501891A1/en unknown
- 2014-08-21 DO DO2014000193A patent/DOP2014000193A/es unknown
- 2014-08-21 IL IL234252A patent/IL234252A/en active IP Right Grant
- 2014-08-21 NI NI201400094A patent/NI201400094A/es unknown
- 2014-08-22 GT GT201400179A patent/GT201400179A/es unknown
- 2014-09-10 MA MA37344A patent/MA35937B1/fr unknown
- 2014-09-17 CR CR20140424A patent/CR20140424A/es unknown
- 2014-09-23 CO CO14210706A patent/CO7160018A2/es unknown
-
2015
- 2015-06-16 HK HK15105709.4A patent/HK1205117A1/xx unknown
- 2015-09-01 US US14/842,141 patent/US9598391B2/en active Active
-
2017
- 2017-01-26 US US15/416,684 patent/US9987249B2/en active Active
-
2019
- 2019-09-05 HR HRP20191606 patent/HRP20191606T1/hr unknown
- 2019-09-10 CY CY20191100947T patent/CY1122017T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20140103A7 (es) | Compuestos de cromano sustituidos como modulares del receptor sensible al calcio | |
| CL2017001984A1 (es) | Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr).(solicitud divisional 3355-2014) | |
| DOP2015000054A (es) | Derivados de c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso | |
| DOP2016000144A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| CO2017006174A2 (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y oesteoartritis | |
| DOP2014000115A (es) | Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
| GT201500138A (es) | Novedososo derivados de bencimidazol como antagonistas de ep4 | |
| CO6771439A2 (es) | Inhibidores de benzodioxano de la producción de leucotrieno | |
| CO6670575A2 (es) | Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen | |
| UY33199A (es) | 5-alquinil-pirimidinas. | |
| UY32574A (es) | Antagonistas del receptor cxcr3 | |
| CR20150425A (es) | Compuestos azabencimidazol como inhibidores de las isozimas pde4, para el tratamiento del sistema nervioso central y otros desórdenes | |
| CL2015002434A1 (es) | Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina. | |
| NI201500050A (es) | Benzamidas | |
| DOP2014000114A (es) | Nuevos 2hindazoles como antagonistas del receptor ep2 | |
| CR20160460A (es) | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados | |
| UY36209A (es) | Derivados de la pirazina como agonistas moduladores del receptor gpr40 y composiciones farmacéuticas que los contienen | |
| ECSP11011454A (es) | 5-alquinil-piridinas | |
| IN2015MN00421A (es) | ||
| UY33230A (es) | Aminotiazolonas como moduladores del receptor alfa relacionados con estrógeno | |
| CR20160215A (es) | Espiro-oxazolonas | |
| UY33214A (es) | Compuestos de aril-bencil-amina | |
| UY32718A (es) | Compuestos derivados de 1, 3, 4-tiadiazol, útiles como agonistas del receptor de esfingosina 1-fosfato | |
| CU20080116A7 (es) | 3-aminociclopentanocarboxamidas como muduladores de receptores de quimioquinas | |
| CU20130108A7 (es) | Novedosos derivados heterocíclicos |